Volume 11, Number 8—August 2005
Research
HIV-1 Genetic Diversity in Antenatal Cohort, Canada
Bertine S. Akouamba*†, Janique Viel*, Hugues Charest‡, Natacha Merindol*†, Johanne Samson*, Normand Lapointe*†, Bluma G. Brenner§, Richard Lalonde¶, P. Richard Harrigan#, Marc Boucher*†, and Hugo Soudeyns*†
Table
Viral and immune parameters in study participants*
| Overall |
Treatment naive |
||||||
|---|---|---|---|---|---|---|---|
| Median (IQR) viral load (log copies/mL)† | % viral load <2.7 (n)‡ | % viral load <1.7 (n)‡ | Median (IQR) CD4+ count (cells/μL)† | % receiving ARV therapy (n)‡ | Median (IQR) viral load (log copies/mL)† | Median (IQR) CD4+ cell count in treatment-naive patients (cells/μL)† | |
| HIV-1 B clade | 3.61 (1.71) | 28.8 (17) | 11.9 (7) | 360 (285) | 44.1 (26) | 3.95 (1.38) | 418 (278) |
| HIV-1 non-B clade | 3.52 (1.39) | 22.7 (10) | 2.27 (1) | 351 (220) | 20.5 (9) | 3.53 (0.94) | 327 (208) |
| p value | 0.927 | 0.508 | 0.316 | 0.476 | 0.0102§ | 0.143 | 0.107 |
*HIV-1 viral load and CD4+ cell counts were measured as described in Patients and Methods. Significance of differences between groups was tested by Kruskal-Wallis test or Fisher exact test. Analysis was carried out on the whole study group (N = 103) or restricted to those who did not receive treatment (n = 61). IQR, interquartile range; ARV, antiretroviral.
†Kruskal-Wallis test.
‡Fisher exact test.
§Statistically significant (p<0.05) by directional test.
Page created: April 23, 2012
Page updated: April 23, 2012
Page reviewed: April 23, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.